$CRBP News
Last published 2d ago
- 2d agoCRBPCorbus Pharmaceuticals Holdings, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 7.01 Item 9.01
- 2d agoCRBPCorbus Pharmaceuticals Reports Q3 2026 Financial Results and Provides a Corporate UpdateGlobeNewswireNORWOOD, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage company focused on developing new therapies in oncology and obesity, today provided a corporate update and reported financial results for the 2026 third quarter ended September 30, 2026.
- 3d agoCRBPGUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - CORBUS PHARMACEUTICALS HOLDINGS INCEarnings Call TranscriptsGood morning, everyone, and welcome to this first session of the third annual Guggenheim Healthcare Innovation Conference. My name is Paul Jang. I'm a biotech analyst with Guggeheim, and I'm very excited to be welcoming
- 3d agoCRBPGUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - CORBUS PHARMACEUTICALS HOLDINGS INCEarnings Call TranscriptsGood morning, everyone, and welcome to this first session of the third annual Guggenheim Healthcare Innovation Conference. My name is Paul Jang. I'm a biotech analyst with Guggeheim, and I'm very excited to be welcoming
- 1w agoCRBPCorbus Pharmaceuticals to Participate in Upcoming Investor Conferences in NovemberGlobeNewswireNORWOOD, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on oncology and obesity, today announced that Yuval Cohen, Ph.D., Chief Executive
- 3w agoCRBPCorbus Pharmaceuticals to Present Late Breaking CRB-913 Data from Canyon-1 Study at Obesity Week® 2026GlobeNewswireNORWOOD, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced that late breaking data
- 1mo agoCRBPCorbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of ObesityGlobeNewswireCRB-913 demonstrated statistically significant and clinically meaningful mean weight loss of 5% at 60 mg after 12 weeks with no plateau observedCRB-913 was generally well tolerated with psychiatric adverse events
- 2mo agoCRBPCorbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In ObesityGlobeNewswireNORWOOD, Mass., Sept. 11, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on developing new therapies in oncology and obesity, today announced that the
- 2mo agoCRBPCorbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireNORWOOD, Mass., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced the grant of inducement
- 3mo agoCRBPCorbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate UpdateGlobeNewswireObtained FDA clearance to proceed with registrational study (TEMPO-1) of CRB-701 in 2L oropharyngeal cancer and expect to initiate enrollment in September 2026Concluded last patient last visit in CANYON-1 Phase 1b study
- 3mo agoCRBPCorbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of ObesityGlobeNewswireDose-finding Phase 1b study (n=240) on track for topline data in September 2026CANYON-1 follows promising data from Phase 1a SAD/MAD study that demonstrated differentiated GI tolerability from GLP-1 classCRB-913 yielded
- 3mo agoCRBPCorbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal CancerGlobeNewswireCompany expects to initiate enrollment in TEMPO-1 in September 2026OPSCC is estimated to represent 1 in 2 head and neck cancer patients in the 2L setting in the U.S. with approximately 14,000 patients eligible annually
- 4mo agoCRBPCorbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical OfficerGlobeNewswireNORWOOD, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), a clinical-stage company focused on developing promising new therapies
- 5mo agoCRBPCORBUS PHARMACEUTICALS HOLDINGS, INC. JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN NEW YORK - CORBUS PHARMACEUTICALS HOLDINGS INCEarnings Call TranscriptsHello, everyone. I'm Amin Makarim, one of the biotech analysts here at Jeff Bees. I'm happy to introduce and welcome Yuval Cohen, CEO of Corbis. This is a fireside chat format, and with that, thank you for joining us tod
- 5mo agoCRBPCorbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical CancersGlobeNewswireData affirms Corbus strategy of targeting tumor types with elevated Nectin-4 expression and clear unmet medical needs while providing an attractive commercial path forward Confirmed ORR of 42.9% observed in 2L
- 5mo agoCRBPKRYSCorbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference CallGlobeNewswireNORWOOD, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity, today announced that
- 6mo agoCRBPIPSCCorbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of DirectorsGlobeNewswireNORWOOD, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity, today announced the
- 6mo agoCRBPCorbus Pharmaceuticals to Participate in Upcoming Investor ConferencesGlobeNewswireNORWOOD, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity, today announced that
- 6mo agoCRBPCorbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate UpdateGlobeNewswireReached broad alignment with the FDA on the registration path for CRB-701 for 2L treatment in head and neck squamous cell carcinoma (HNSCC) and cervical cancer with CRB-701Announced presentation of updated CRB-701 data
- 6mo agoCRBPCorbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ASCO 2026GlobeNewswireNORWOOD, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on promising new therapies in oncology and obesity, today announced that it will
- 6mo agoCRBPCorbus Pharmaceuticals Announces Abstracts Accepted for Presentation at ASCO 2026 Featuring Updated Clinical Data for CRB-701GlobeNewswireNORWOOD, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on promising new therapies in oncology and obesity, today announced that updated
- 7mo agoCRBPCorbus Pharmaceuticals Announces Last Patient First Visit in CANYON-1 Study of CRB-913 for the Treatment for ObesityGlobeNewswireOn track to complete 16-week, dose-finding Phase 1b study (n=240) in summer 2026 Phase 1b data will build upon Phase 1a findings that demonstrated weight loss of nearly 3% at 14 days in individuals with obesity CRB-913
- 7mo agoCRBPCorbus Pharmaceuticals Announces Broad Alignment with FDA on Registration Path for CRB-701 in Second-Line HNSCC and Cervical CancerGlobeNewswireFDA feedback enables Corbus to proceed with proposed registrational study design and endpoints to support potential accelerated approval in second-line HNSCC and cervical cancer Updated CRB-701 monotherapy data accepted
- 8mo agoCRBPCorbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate UpdateGlobeNewswirePresented data at ESMO 2025 demonstrating promising efficacy with CRB-701 in head and neck squamous cell carcinoma (HNSCC) and cervical cancerCRB-701 data for both indications is expected in mid-2026 with focus on
- 9mo agoCRBPCorbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences ConferenceGlobeNewswireNORWOOD, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical-stage company focused on oncology and obesity, today announced that Yuval Cohen, Ph.D., Chief Executive
- 10mo agoCRBPCorbus Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireNORWOOD, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical-stage company focused on oncology and obesity, today announced that Yuval Cohen, Ph.D., Chief Executive
- 11mo agoCRBPCorbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight LossGlobeNewswireCRB-913 was safe and well-tolerated across all doses studiedDaily neuropsychiatric assessments using CSSRS, PHQ-9, and GAD-7 were negative for all participantsA placebo-adjusted mean weight loss of 2.9% was observed at
- 11mo agoCRBPCorbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025GlobeNewswireNORWOOD, Mass., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical stage company focused on oncology and obesity, announced the Company's plan to release results of its
- 1y agoCRBPCorbus Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides a Corporate UpdateGlobeNewswirePresented robust CRB-701 clinical data at ESMO 2025 - 3.6 mg/kg dose generated ORR of 47.6% in HNSCC, 37.5% in cervical cancer and 55.6% in mUCCRB-701 HNSCC registrational study planned to start mid-2026Completed $75
- 1y agoCRBPCorbus Pharmaceuticals to Participate in Upcoming Investor ConferencesGlobeNewswireNORWOOD, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), an oncology and obesity company, today announced it will be participating in the
- 1y agoCRBPCorbus Pharmaceuticals Announces Pricing of Public OfferingGlobeNewswireNORWOOD, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), an oncology and obesity company, today announced the pricing of an underwritten public
- 1y agoCRBPCorbus Pharmaceuticals Announces Proposed Public OfferingGlobeNewswireNORWOOD, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), an oncology and obesity company, today announced that it plans to offer and sell shares
- 1y agoCRBPCorbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25GlobeNewswire3.6 mg/kg dose generated ORR of 47.6% in HNSCC, 37.5% in cervical cancer and 55.6% in mUCCRB-701 continues to demonstrate a favorable safety and tolerability profileRegistrational studies planned to start in
- 1y agoCRBPCorbus Pharmaceuticals to Present CRB-701 Phase 1/2 Data at ESMO 2025GlobeNewswireData to be presented for 167 enrolled participants of which 122 were evaluable for efficacy Company to host HNSCC KOL event to review and discuss data NORWOOD, Mass., Oct. 14, 2025
- 1y agoCRBPCorbus Pharmaceuticals to Participate in the Upcoming Piper Sandler Virtual Oncology SymposiumGlobeNewswireNORWOOD, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), a clinical stage oncology and obesity company, today announced that Yuval Cohen, Ph.D.,
- 1y agoCRBPCorbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ESMO 2025GlobeNewswireNORWOOD, Mass., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), a clinical stage oncology and obesity company, today announced that it will host an
- 1y agoCRBPFDA Grants Fast Track Designation to Corbus Pharmaceuticals' Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell CarcinomaGlobeNewswireDose optimization data from the Phase 1/2 study to be presented next month at ESMO 2025Second Fast Track designation granted by FDA for CRB-701 NORWOOD, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals
- 1y agoCRBPCorbus Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides a Corporate UpdateGlobeNewswirePhase 1/2 dose expansion data for Nectin-4 targeting ADC CRB-701 to be presented at ESMO 2025Initiated 7-day MAD portion of Phase 1 study for obesity drug CRB-913All three clinical programs (CRB-701, CRB-913, CRB-601) on
- 1y agoCRBPCorbus Pharmaceuticals Announces Upcoming Presentation of Dose Expansion Phase 1/2 Clinical Data for its Nectin-4 Targeting ADC CRB-701 at the 2025 ESMO Annual CongressGlobeNewswireNORWOOD, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical-stage company focused on oncology and obesity, announced today that an abstract on updated clinical data
- 1y agoCRBPCorbus Pharmaceuticals Initiates Multiple Ascending Dose Portion of Phase 1 Study of Highly Peripherally Restricted CB1 Inverse Agonist CRB-913 for the Treatment of ObesityGlobeNewswireNo treatment-related neuropsychiatric events seen to date in SAD portion of Phase 1MAD study on track for completion in Q3 2025 NORWOOD, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc.
- 1y agoCRBPCorbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with PembrolizumabGlobeNewswireCombination cohort initiated following successful review of monotherapy cohortOver 100 participants dosed to-date in monotherapy cohortPriority are Head and Neck Squamous Cell Carcinoma (HNSCC) and cervical cancerData
- 1y agoCRBPCorbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity SymposiumGlobeNewswireNORWOOD, Mass., June 24, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will
- 1y agoCRBPCorbus Pharmaceuticals to Present at the Jefferies Global Healthcare ConferenceGlobeNewswireNORWOOD, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will provide
- 1y agoAKTXCRBPQURECorbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board ChairGlobeNewswireNORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical-stage company focused on oncology and obesity, today announced the appointment of Rachelle Jacques as
- 1y agoCRBPCorbus Pharmaceuticals to Present at the 2025 RBC Capital Markets Global Healthcare ConferenceGlobeNewswireNorwood, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will
- 1y agoCRBPCorbus Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides a Corporate UpdateGlobeNewswireDose optimization and RP2D determination on schedule for completion in Q4 2025 for the Nectin-4 ADC CRB-701 in HNSCC, cervical and mUC tumorsSAD/MAD study on schedule for completion in Q3 2025 for the anti-obesity CB1
- 1y agoCRBPCorbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of ObesityGlobeNewswireCB1 inverse agonism is a clinically validated mechanism to induce weight loss CRB-913 is markedly more peripherally restricted compared to monlunabant and rimonabantSAD/MAD Phase 1 trial scheduled for completion Q3 2025
- 1y agoCRBPCorbus Pharmaceuticals Reports Q4 and 2024 Financial Results and Provides a Corporate UpdateGlobeNewswireCRB-701 Nectin-4 targeting ADC demonstrates encouraging results in Phase 1 Western study Fast Track Designation granted by FDA for CRB-701 to treat metastatic cervical cancerCRB 913 SAD/MAD obesity study expected to
- 1y agoCRBPCorbus Pharmaceuticals to Participate in Upcoming Investor ConferencesGlobeNewswireNORWOOD, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will
- 1y agoCRBPCRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025GlobeNewswireStudy mirrored 4 highest doses used in China dose escalation study presented at ASCO 2024 Safety, tolerability and PK comparable to China dataset with no DLTs observed in either study Low levels of peripheral neuropathy